Articles
-
Comments to CMS on Proposed Guidance for Coverage with Evidence Development
Eleven Schaeffer fellows cosigned a comment letter to Centers for Medicaid and Medicare Services providing recommendations on the proposed Coverage with Evidence Development Guidance.
Categorized in -
Lower-Middle-Class Americans Near Retirement Are Worse Off Than 20 Years Ago, New USC and Columbia Study Shows
‘Forgotten middle’ Americans face poorer health, worse economic outcomes and lower homeownership rates, along with increased disability in old age.
Categorized in -
Beware of the Government’s Healthcare ‘Truth’ Peddlers
The Biden administration’s efforts to regulate, either explicitly or through indirect government coercion, what it deems to be “misinformation” in healthcare not only runs counter to our shared values but can be dangerous to our health.
Categorized in -
Response to Congressional Request for Information about Regulating Cannabidiol
Schaeffer experts submitted a comment letter responding to a recent request for information (RFI) related to cannabidiol.
Categorized in -
Intensive Lifestyle Counseling and Education by Health Specialists Associated With Higher Employment Rate Among People With Type 2 Diabetes
USC Schaeffer Center research finds intensive lifestyle intervention for people with type 2 diabetes – including weekly counseling on diet and exercise – is associated with increased employment. Researchers say the results suggest the potential of better chronic disease management for improving long-term labor market outcomes.
Categorized in -
There’s an Easy Way to Increase Rates of COVID Booster Vaccinations
USC research finds that the answer to getting more shots into arms is just a text message or email away.
Categorized in -
Inflation Reduction Act’s Cap on Insulin Out-of-Pocket Costs Boosts Prescription Fills
Published in JAMA, the findings from USC and University of Wisconsin–Madison researchers suggest the policy cut the number of Medicare enrollees who weren’t filling insulin because of cost.
Categorized in -
Blame Capitalism? Why Hundreds of Decades-Old Yet Vital Drugs Are Nearly Impossible to Find
The shortages, which have been going on for years, have typically affected only low-cost generics rather than profitable brand-name drugs.
Categorized in -
Centers for Disease Control and Prevention Guideline for Prescribing Opioids, 2022—Need for Integrating Dosing Benchmarks with Shared Decision-Making
A fully individualized, unstructured decision-making process
will not be adequate to protect patients receiving long-term opioid
therapy.Categorized in -
Congress Can Eradicate Hepatitis C and Reduce the Deficit at the Same Time
The initiative comes with a $12.3 billion price tag — and over 10 years, the savings in health care costs will reach $18.1 billion.
Categorized in